

**DLL3**  
**Catalog # PVGS1830****Specification**

---

**DLL3 - Product Information**

Primary Accession [Q9NYJ7-1](#)  
**Species**  
Human

**Sequence**  
Val311-Ala479

**Purity**  
> 95% as determined by Bis-Tris PAGE  
> 95% as determined by HPLC

**Endotoxin Level**  
Less than 1EU per µg by the LAL method.

**Biological Activity**  
Immobilized DLL3 Domain (311-479), His&Avi, Human (Cat.No.: Z03951) at 1 µg/ml (100 µl/Well) on the plate can bind Anti-DLL3 Antibody, hFc Tag

**Expression System**  
HEK293

**Theoretical Molecular Weight**  
21.20 kDa

Formulation **Lyophilized from a 0.22 µm filtered solution in PBS, (pH 7.4).**

**Reconstitution**  
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH<sub>2</sub>O more than 100 µg/ml.

**Storage & Stability**  
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

**DLL3 - Additional Information**

**Target Background**  
Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand. It is highly expressed on the surface of Small cell lung cancer (SCLC) and other neuroendocrine tumors. And its expression promotes SCLC migration and invasion. DLL3 agents are evaluated in several ongoing clinical studies in SCLC and other neuroendocrine tumors.

**DLL3 - Protein Information**

## **DLL3 - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

## **DLL3 - Images**